We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive third-quarter sales performance.

Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Puma Biotech (PBYI) or Amgen (AMGN). But which of these two stocks is more attractive to v...

TScan Therapeutics is developing TCR T-cell therapies for cancer using a transposon-based T cell engineering method. The company aims to target a broader patient population by addressing a wide ran...

We believe that AMGN has overpaid for HZNP's pipeline, since most of its upside potential is attributed to price increases instead of the expanding TAM. The growing debt may also pose headwinds to ...

Amgen finally closed its acquisition of Horizon Therapeutics despite a regulatory hiccup. Horizon has a relatively impressive portfolio although, like Amgen, it has growth issues.

The company's growth rate has been underwhelming in recent years. Amgen relied on acquisitions in recent years to enhance its growth opportunities.

In the closing of the recent trading day, Amgen (AMGN) stood at $285.04, denoting a +0.51% change from the preceding trading day.

A Leerink Partner analyst expects accelerating pipeline news flow for Amgen (AMGN).

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling.

Plug Power (PLUG) shares close Wednesday higher after raising its forward revenue outlook through 2027. EV infrastructure company ChargePoint's (CHPT) stock tumbles while raising $232 million in it...

Amgen (AMGN) closed at $267.47 in the latest trading session, marking a +0.9% move from the prior day.

Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditi...

Amgen Inc. said it would continue to work closely with the Food and Drug Administration to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer, after an advisor...

Advisers to the U.S. Food and Drug Administration on Thursday found that data from a late-stage trial was not reliable enough to support traditional approval of Amgen's Lumakras for patients with a...